Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.

Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
The market would gain traction in the developing regions of Asia-Pacific and third-world countries such as Africa and Latin America. The large undiagnosed patient population, rapid urbanization, rising disposable income, improved government funding towards cancer and growing awareness about prostate cancer would be some of the prime reasons responsible for the unparalleled market growth in these regions. However, oncologists/urologists reluctance towards adoption of these premium treatments in countries like India and China would continue to remain a key challenge for the leading innovators.

Market Analysis and Insights: Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market
The research report studies the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market size is projected to reach US$ 10640 million by 2026, from US$ 7869.7 million in 2020, at a CAGR of 5.2% during 2021-2026.

Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Scope and Segment
The global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.

Segment by Type, the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market is segmented into
Oral Therapy
Injectable Therapy

Segment by Application, the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market is segmented into
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)

Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa

The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.

The major vendors covered:
Astellas Inc.
Johnson & Johnson
Sanofi S.A
Dendreon Corporation
Bayer AG

Frequently Asked Questions